Satellos (NASDAQ: MSLE) holders back board and reappoint PwC auditor

Rhea-AI Filing Summary

Satellos Bioscience Inc. reports the results of its Annual Meeting of Shareholders held on June 17, 2026. Shareholders present or represented by proxy accounted for 55.3% of the issued and outstanding common shares, providing a solid participation base for governance decisions.

All director nominees listed in the May 14, 2026 management information circular were elected, with most receiving over 99% of votes cast in their favor. Satellos shareholders also approved the re-appointment of PricewaterhouseCoopers LLP as the Company’s auditors.

The filing also reiterates that Satellos is a clinical-stage drug development company advancing SAT-3247 in two Phase II trials for degenerative muscle diseases, including Duchenne muscular dystrophy, and includes standard forward-looking statement disclosures outlining development and regulatory risks.

Key Figures

Shareholder turnout: 55.3% of common shares Votes for Frank Gleeson: 9,473,905 votes (99.94% for) Votes for Stephanie Brown: 8,741,404 votes (92.22% for) +2 more

5 metrics

Shareholder turnout 55.3% of common shares Participation at Annual Meeting of Shareholders on June 17, 2026

Votes for Frank Gleeson 9,473,905 votes (99.94% for) Director election at 2026 Annual Meeting

Votes for Stephanie Brown 8,741,404 votes (92.22% for) Director election at 2026 Annual Meeting

Votes for Iris Loew-Friedrich 7,939,800 votes (83.76% for) Director election at 2026 Annual Meeting

Votes for Mark Nawacki 9,477,041 votes (99.98% for) Director election at 2026 Annual Meeting

Key Terms

Annual Meeting of Shareholders, management information circular, Phase II clinical trials, forward-looking information, +1 more

5 terms

Annual Meeting of Shareholders financial

"announced today the results of its Annual Meeting of Shareholders held June 17, 2026"

A yearly gathering where a company’s owners (shareholders) vote on key items like electing the board, approving executive pay, and ratifying auditors, and receive updates on performance and strategy. Think of it as an annual town hall for owners: it matters to investors because outcomes and disclosures can affect leadership, corporate direction, dividend and governance policies, and therefore the company’s risk and potential return.

management information circular regulatory

"all the nominees listed in the management information circular dated May 14, 2026"

A management information circular is a document sent to shareholders ahead of a company meeting that explains who is asking for votes, what decisions will be made, and why management recommends a particular outcome. Like an instruction booklet and argument sheet combined, it lays out details such as board nominees, executive pay, major transactions and any conflicts, helping investors decide how to vote and judge whether leadership choices could affect the company’s future value.

Phase II clinical trials medical

"in two Phase II clinical trials: BASECAMP in pediatrics and TRAILHEAD in adults"

Phase II clinical trials are studies that evaluate whether an experimental drug or therapy actually works and is reasonably safe in a larger group of patients after initial safety checks. Investors care because results provide the first meaningful evidence of effectiveness and side effects—like a prototype tested with real users—informing whether a program is likely to advance, shaping a drug’s future value and the company’s funding and partnership prospects.

forward-looking information regulatory

"This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws"

Forward-looking information are predictions, plans, estimates or expectations about a company’s future performance, results or events, such as sales forecasts, project timelines, or anticipated costs. It matters to investors because these statements guide expectations but rely on assumptions and uncertain factors—like a weather forecast for a business—so investors should treat them as informed guesses rather than guarantees and consider the risks and possible changes behind the numbers.

disease-modifying treatment medical

"SAT-3247 is being evaluated as a potential disease-modifying treatment, initially for DMD"

A disease-modifying treatment is a therapy that changes the underlying course of a chronic illness rather than only easing symptoms, like repairing a leak in a roof instead of just mopping up the water. For investors it matters because such treatments can sustain patient benefits over time, command higher prices, shift long-term healthcare costs and create lasting market advantages or risks depending on how widely and quickly they are adopted and reimbursed.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2026

Commission File Number: 001-43107

SATELLOS BIOSCIENCE INC.
(Translation of registrant's name into English)

15 Allstate Parkway, Suite 600, Markham,
Ontario, Canada L3R 5B4
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [   ]      Form 40-F [ X ]

DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K

Exhibit		Description
99.1		Satellos Bioscience Announces Results of Annual Meeting of Shareholders

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		SATELLOS BIOSCIENCE INC.
		(Registrant)
Date: June 17, 2026		/s/ Elizabeth Williams, CPA, CA
		Elizabeth Williams, CPA, CA
		Chief Financial Officer

EXHIBIT 99.1

Satellos Bioscience Announces Results of Annual Meeting of Shareholders

TORONTO, June 17, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, announced today the results of its Annual Meeting of Shareholders held June 17, 2026 (the “Meeting”).

Satellos is pleased to announce that all the nominees listed in the management information circular dated May 14, 2026 (the “Circular”) were elected as directors. Shareholders present at the Meeting or represented by proxy totaled 55.3% of the issued and outstanding common shares of the Company.

The results of the vote are detailed below:

Director	Votes For		% For		Votes Against		% Against
Frank Gleeson	9,473,905		99.94		5,348		0.06
Franklin M. Berger	9,478,576		99.99		677		0.01
Brian Bloom	9,476,755		99.97		2,498		0.03
Stephanie Brown	8,741,404		92.22		737,849		7.78
Selwyn Ho	9,473,538		99.94		5,715		0.06
Iris Loew-Friedrich	7,939,800		83.76		1,539,453		16.24
Geoff Mackay	9,449,959		99.69		29,294		0.31
Adam Mostafa	9,450,311		99.69		28,942		0.31
Mark Nawacki	9,477,041		99.98		2,212		0.02

Satellos shareholders also voted in favor of the re-appointment of PricewaterhouseCoopers LLP as auditors of the Company.

Please refer to Circular available on SEDAR+ (sedarplus.ca) and EDGAR (sec.gov) for more details on the matters covered at the Meeting. Final voting results on all matters voted on at the Meeting will also be filed on SEDAR+ and EDGAR.

ABOUT SATELLOS BIOSCIENCE INC.

Satellos is a clinical-stage drug development company advancing SAT-3247, a first-of-its-kind, orally administered small molecule therapy designed to reset the body’s natural muscle repair and regeneration process in degenerative muscle diseases. SAT-3247 is being evaluated as a potential disease-modifying treatment, initially for DMD, in two Phase II clinical trials: BASECAMP in pediatrics and TRAILHEAD in adults. SAT-3247 targets AAK1, a protein that is a key regulator of the body’s natural muscle repair and regeneration biology, which Satellos discovered is disrupted in DMD and other degenerative conditions. By inhibiting AAK1, SAT-3247 is designed to re-establish a critical biochemical signal needed to guide this process, in a dystrophin-independent manner. This mechanistic feature offers SAT-3247 the potential for broad applicability as either a stand-alone treatment to potentially enhance muscle and function, or as adjunctive therapy alongside other approaches. Satellos has identified additional degenerative muscle diseases where enhancing muscle repair and regeneration may have therapeutic benefit and plans to pursue these opportunities in future clinical development. For more information, visit www.satellos.com.

NOTICE ON FORWARD-LOOKING STATEMENTS

This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding Satellos and its business, which may include, but are not limited to, statements regarding the potential for SAT-3247 to represent a disease modifying approach to the therapeutic treatment of people living with Duchenne; anticipated benefits to patients from a small molecule treatment for Duchenne; the potential of our approach in other degenerative muscle diseases and our plans to pursue those opportunities. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, occurrences or developments, are “forward-looking information or statements.” Often, but not always, forward-looking information or statements can be identified by the use of words such as “shall”, “intends”, “believe”, “plan”, “expect”, “intend”, “estimate”, “anticipate”, “potential”, “prospective” , “assert” or any variations (including negative or plural variations) of such words and phrases, or state that certain actions, events or results “may”, “might”, “can”, “could”, “would” or “will” be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. These statements are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, risks relating to the pharmaceutical and bioscience industry (including the risks associated with preclinical and clinical trials and regulatory approvals), the research and development of therapeutics, the results of preclinical and clinical trials, general market conditions and equity markets, economic factors and management’s ability to manage and to operate the business of the Company generally, including inflation and the costs of operating a biopharma business, and those risks and uncertainties described in more detail in the “Risk Factors” section of Satellos’ Annual Information Form dated March 27, 2026 (which is located on Satellos’ profile at www.sedarplus.ca) and in Satellos’ public filings on SEDAR+ (sedarplus.ca) and EDGAR (sec.gov). Although Satellos has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Satellos does not undertake any obligation to publicly update or revise any forward-looking statement, whether resulting from new information, future events, or otherwise

CONTACTS

Investors: Dan Ferry, LifeSci Advisors, daniel@lifesciadvisors.com
Media: Emily Williams, Senior Director of Communications, media@satellos.com

FAQ

What did Satellos Bioscience (MSLE) announce in this Form 6-K?

Satellos Bioscience announced the results of its Annual Meeting of Shareholders. All director nominees were elected, and PricewaterhouseCoopers LLP was re-appointed as auditors, confirming the company’s proposed governance slate and audit arrangements for the coming year.

What was shareholder turnout at the Satellos Bioscience (MSLE) 2026 Annual Meeting?

Shareholders representing 55.3% of Satellos’ issued and outstanding common shares were present or represented by proxy. This participation level provided the voting base that elected directors and approved the re-appointment of PricewaterhouseCoopers LLP as the company’s auditors.

Were all Satellos Bioscience (MSLE) director nominees elected at the 2026 meeting?

Yes, all director nominees listed in the May 14, 2026 management information circular were elected. Most received over 99% support, with individual vote totals and percentages disclosed, indicating broad shareholder backing for the proposed board composition.

Which auditor did Satellos Bioscience (MSLE) shareholders approve at the 2026 meeting?

Satellos shareholders voted in favor of re-appointing PricewaterhouseCoopers LLP as auditors. This decision maintains continuity in the company’s external audit arrangements, as disclosed in the voting results from the Annual Meeting of Shareholders held June 17, 2026.

What is SAT-3247, the lead program described by Satellos Bioscience (MSLE)?

SAT-3247 is an orally administered small molecule therapy designed to reset muscle repair and regeneration. Satellos is evaluating it as a potential disease-modifying treatment for Duchenne muscular dystrophy in two Phase II trials, BASECAMP in pediatrics and TRAILHEAD in adults.

What risks does Satellos Bioscience (MSLE) highlight in its forward-looking statements?

Satellos notes risks related to pharmaceutical and bioscience development, including preclinical and clinical trial outcomes, regulatory approvals, market conditions, inflation, and operating costs. It refers investors to its March 27, 2026 Annual Information Form and other filings for detailed risk factors.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE 20.9 KB